2500 liver cancer patients tracked to see if new drugs beat old standard
NCT ID NCT07233759
First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study looks back at the medical records of 2500 liver cancer patients treated at a major hospital in Taiwan between 2019 and 2024. Researchers want to see how well newer drugs like Pembrolizumab, Atezolizumab, and Lenvatinib work compared to the older drug sorafenib. They will measure survival, cancer shrinkage, and side effects to understand which treatments are most effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
Conditions
Explore the condition pages connected to this study.